CRC panel, thyroid cancer kits, 6/17
June 2017—EntroGen announced CE-IVD marking of its Colorectal Cancer Panel (CRC), Thyroid Cancer Mutation Analysis kit (THDNA), and Thyroid Cancer Fusion Gene Detection kit (THRNA).
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Olympus microscopes, 6/17
June 2017—The Olympus CX43 and CX33 microscopes are designed to keep users comfortable during long periods of use, maximizing work efficiency. Features of the microscopes that minimize user fatigue include a stage that is 70 mm lower than the previous model, resulting in a large working space under the eyepieces, which makes it easier to check or swap samples with just one hand; a stage knob and co-axial focus knobs that are designed lower to the microscope base so users can reach the controls while their forearms remain resting on the desk; and a low-positioned revolving nosepiece that accommodates up to five objectives and enables users to quickly change magnification with minimal arm movement.
Quest, PeaceHealth agreement, 6/17
June 2017—Quest Diagnostics and PeaceHealth have formed a two-part arrangement to enhance the delivery of laboratory services to communities in Oregon, Washington, and Alaska.
NGS cancer panels, 6/17
June 2017—Oxford Gene Technology has expanded its SureSeq myPanel NGS Custom Cancer Panel content. The expanded content covers more than 70 genes optimized for hematology and solid tumors including breast, colorectal, lung, ovarian and prostate cancer, glioma, melanoma, sarcoma, leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome.
Deep learning AI analytics platform, 6/17
June 2017—Fimmic launched its next-generation WebMicroscope Deep Learning Platform. Fimmic’s cloud platform brings deep learning artificial-intelligence-based image analysis to pathologists and researchers, no matter the size of a project.
FDA-cleared next-gen troponin T test, 6/17
June 2017—Roche received 510(k) clearance for its Elecsys Troponin T Gen 5 STAT blood test for patients with a suspected heart attack. With this clearance, according to a company statement, Roche is the first IVD company in the U.S. to provide next-generation troponin testing for patients as an aid in the diagnosis of myocardial infarction, enabling clinicians to more accurately identify patients experiencing a heart attack.
Pan-ethnic solution for carrier status research, 6/17
June 2017—Thermo Fisher Scientific released its CarrierScan Assay, a high-throughput, microarray-based assay that provides molecular genetics laboratories with a consolidated and automated single pan-ethnic solution for expanded carrier status research.
Multiplexed analysis to detect gene fusions, 5/17
May 2017—Agena Bioscience announced a comparative study published in Scientific Reports highlighting the use of its mass-spec-based platform for transcriptome analysis of ALK, ROS1, and RET gene fusions in lung cancer.
Monoclonal antibodies to Shigella, 5/17
May 2017—ViroStat released two sets of monoclonal antibodies to Shigella—one set specific to Shigella sonnei and another set specific to Shigella flexneri 2a. Potential applications for these include direct bacterial detection by ELISA and lateral flow rapid tests.
Molecular flu tests cleared, 5/17
May 2017—Cepheid received FDA clearance to market Xpert Xpress Flu and Xpert Xpress Flu/RSV. Both tests deliver reference-quality molecular results in as little as 20 minutes. The tests are Cepheid’s first Xpress branded products, which are expected to deliver results in 30 minutes or less.